Advancements of molecular imaging and radiomics in pancreatic carcinoma

Table 2 Summary of the main clinical key points of the two EANM/ENETS recommended radiopharmaceuticals[17]

Clinical key points
Radiopharmaceuticals	Main indication	Diagnostic accuracy	False positive findings
68Ga-TATE, TOC, NOC	Staging and restaging any non-insulinoma panNET case; detection of the unknown primary tumour site or early relapse; evaluation in-vivo SRE; selection for PRRT and/or cold SSA	Sensitivity: 86% to 100%; specificity: from 79% to 100%	Pancreatic uncinate process, accessory spleens (including intra-pancreatic, splenules, infectious/inflammatory findings, non-neuroendocrine tumours)
18F-FDG	High grade G2, G3 and NEC; prognosis; rapid tumour progression in earlier diagnosed G1–G2 tumours	Sensitivity: 40% in G1, 60% in G2; 95% in G3 patients	Infectious/inflammatory findings, non-neuroendocrine tumours

This table is adopted from[17]. TATE: Tyr(3)-octreotate; NOC: 1-Nal(3)-octreotide; TOC: D-Phe1-Tyr(3)-octreotide; NEC: Neuroendocrine carcinomas.